Compare Amgen, Inc. (AMGN) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Clorox Co — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Clorox Co trades at $96.56 (market cap $11.68B). The key difference: Amgen, Inc. is far larger — about 16.8× Clorox Co's market cap, and Clorox Co pays the higher dividend (5.14%). Which is the better fit depends on your goals.
| AMGN | CLX | |
|---|---|---|
Market Cap | $196.12B | $11.68B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $131.43 |
52-Week Low | $271.18 | $86.12 |
Enterprise Value | $241.41B | $14.98B |
Dividend Yield | 2.77% | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Clorox (CLX) trades at $96.56, up 3.75% today, but remains down over 7% YTD amid declining sales and profitability concerns. The stock shows a bearish technical trend with key support at $91, while fundamentals reveal strong profitability with an 11.18% net margin and a 5.5% dividend yield. Recent corporate actions include a simplified operating structure and CEO transition, with Q2 2026 earnings pending.
The outlook is mixed: a high dividend and recent earnings beats offer value, but bearish analyst sentiment and sales declines pose risks. Upside exists if restructuring drives growth, yet investor caution is warranted given valuation premiums and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
